Sonnet BioTherapeutics - SONN Income before deduction of interest, taxes and amortization
Sonnet BioTherapeutics maintains a strong image as a developer of targeted cytokines for tumor combat. Monthly EBITDA dynamics demonstrate a cash flow where the value 0.00 represents the current figure. The company achieves operational flexibility through the outsourcing of production and testing. However, growth is constrained by stringent FDA oversight, lobbying pressure, and strict patent protection of technologies.
Sonnet BioTherapeutics Holdings - analytical breakdowns and key metrics (SONN)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Sonnet BioTherapeutics|SONN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc.|SONN - Company Debts|Debt to Book Value Ratio Sonnet BioTherapeutics|SONN - Company Long-Term Debt|Short-Term Debt Sonnet BioTherapeutics|Critical Liquidity sonnetbio.com
- company profitability and valuation multiples indicators:
SONN - Net Income|Future Net Profit Sonnet BioTherapeutics|SONN - P/E Multiple|Future Price to Earnings Multiple Sonnet BioTherapeutics Holdings, Inc.|SONN - PEG Multiple|Company Value to EBITDA Sonnet BioTherapeutics|SONN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Sonnet BioTherapeutics|SONN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth sonnetbio.com|SONN - Earnings per share growth in current year|Net earnings per share change forecast for next year Sonnet BioTherapeutics
Analysis of all company metrics:Sonnet BioTherapeutics - SONN
Investors are assessing the resilience of Sonnet BioTherapeutics (SONN) through the ability of its immunotherapy developments to transform into actual cash flow. This indicator measures net operating income before depreciation and amortization, reflecting the efficiency of the technological platform's utilization regardless of debt load and taxes. An analysis of total EBITDA allows for the determination of whether the scientific foundation is generating value or requires constant external financing.
Competitors of Sonnet BioTherapeutics (SONN)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization kinetabio.com KA|NexImmune (NEXI) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Operating profit before amortization HARP (Harpoon Therapeutics Corp)
